SCHEMBL20607286

SCHEMBL20607286

COC(=O)CC(C)C(=O)c1cc(C)c(O[Si](C)(C)C(C)(C)C)c(Cl)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA1 P02708 2/20 0.35
CHRNG P07510 2/20 0.35
CHRNB1 P11230 2/20 0.35
CHRNB2 P17787 2/20 0.35
SLC6A2 P23975 2/20 0.35
CHRNB4 P30926 2/20 0.35
SLC6A4 P31645 2/20 0.35
CHRNA3 P32297 2/20 0.35
CHRNA4 P43681 2/20 0.35
SLC6A3 Q01959 2/20 0.35
CHRND Q07001 2/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
TAS1R3 Q7RTX0 3/20 0.32
TAS1R1 Q7RTX1 3/20 0.32
TAS1R2 Q8TE23 2/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29628793 1.00 CHRNA1 (0.35) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL28743655 0.86 CHRNA1 (0.35) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL20607356 0.77 PPARA (0.42) KDM4EALDH1A1GAATSHRDRD2
SCHEMBL29628706 0.77 PPARA (0.42) KDM4EALDH1A1GAATSHRDRD2
SCHEMBL20607200 0.76 KDM4E (0.33) KDM4EALDH1A1GAAKMT2ATAS1R3
SCHEMBL29628562 0.76 KDM4E (0.33) KDM4EALDH1A1GAAKMT2ATAS1R3
SCHEMBL20607391 0.73 ALDH1A1 (0.44) KDM4EALDH1A1GAAKMT2ATAS1R3
SCHEMBL29628750 0.73 ALDH1A1 (0.44) KDM4EALDH1A1GAAKMT2ATAS1R3
SCHEMBL20607067 0.73 PTPN1 (0.36) ALDH1A1KMT2ATAS1R3TAS1R1
SCHEMBL13304079 0.72 DRD2 (0.47) SLC6A4ALDH1A1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400520-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-05 US disclosed
CN-108779076-B 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives 大塚制药株式会社 2022-05-03 CN disclosed
EP-3423440-B9 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS OTSUKA PHARMA CO LTD (JP) 2021-07-28 EP disclosed
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-06-10 US disclosed
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-06-10 US disclosed
EP-3423440-B1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS OTSUKA PHARMA CO LTD (JP) 2021-01-06 EP disclosed
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-11 US disclosed
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-11 US disclosed
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-07 US disclosed
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-07 US disclosed
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
EP-3423440-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE Otsuka Pharmaceutical Co., Ltd. (JP) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 CHRNA1 3878/4885CHRNG 4448/4885CHRNB1 4109/4885
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 CHRNA1 3878/4885CHRNG 4448/4885CHRNB1 4109/4885
US-20240400520-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 CHRNA1 3878/4885CHRNG 4448/4885CHRNB1 4109/4885
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 CHRNA1 3878/4885CHRNG 4448/4885CHRNB1 4109/4885
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative VHL, H1-5, PRMT5 CHRNA1 3878/4885CHRNG 4448/4885CHRNB1 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.